Regulatory Considerations for Genome-Edited T-cell Therapies.

Area of Science:

• Biotechnology
• Genomics
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR)-engineered T lymphocytes represent a pioneering cell therapy approach.
• Classical gene therapy vectors were initially used for CAR transgene insertion into T-cell genomes.
• Advancements in genome engineering are driving innovation in therapeutic interventions.

Purpose of the Study:

• To review the current landscape of gene-edited cell products.
• To discuss the integration of gene therapy and genome editing in cellular therapies.
• To examine the scientific, translational, and regulatory oversight of these advanced therapies.

Main Methods:

• Review of scientific literature on gene therapy and genome editing.
• Analysis of translational progress in engineered cell products.
• Examination of regulatory frameworks governing gene-edited cell therapies.

Main Results:

• Clustered regularly interspaced short palindromic repeats (CRISPR)-based technologies enable precise editing of endogenous genes.
• Integration of gene therapy with genome editing is a growing trend in developing novel cellular therapies.
• Enhanced therapeutic efficacy and novel biological functions are key outcomes of combined approaches.

Conclusions:

• Gene-edited cell products represent a new era of precision medicine.
• The convergence of gene therapy and genome editing offers significant therapeutic potential.
• Robust scientific, translational, and regulatory oversight is crucial for the advancement of these technologies.